ArticleEuropean urology open science2026
Consolidative Radical Cystectomy Following Neoadjuvant Tislelizumab Plus Gemcitabine and Cisplatin in Clinically Lymph Node-positive Bladder Cancer: A Prospective Study.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04570410 (Trials of Primary Excision Combined With Preoperative Neoadjuvant Therapy and Adjuvant Therapy Was Used as a First-line Comprehensive Therapy for Oligometastasis of Urothelial Carcinoma（UC）.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trials of Primary Excision Combined With Preoperative Neoadjuvant Therapy and Adjuvant Therapy Was Used as a First-line Comprehensive Therapy for Oligometastasis of Urothelial Carcinoma（UC）.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Although multiple clinical trials have demonstrated that neoadjuvant immune checkpoint inhibitors combined with gemcitabine plus cisplatin achieve promising pathological complete response (pCR) rates in muscle-invasive bladder cancer patients, these studies generally excluded those with lymph node metastasis. This study aims to evaluate the efficacy and prognostic outcomes of neoadjuvant tislelizumab combined with gemcitabine plus cisplatin, followed by consolidative radical cystectomy (RC), in patients with clinically lymph node-positive bladder cancer. Methods: In this prospective study (NCT04570410), patients with cT2-4N1-3M0 bladder cancer were enrolled. The treatment regimen consisted of tislelizumab (200 mg on day 8), gemcitabine (1000 mg/m Key findings and limitations: A total of 30 patients were enrolled, of whom 28 met the inclusion criteria and 19 completed neoadjuvant therapy followed by consolidative RC. The overall clinical complete response rate was 31%. Final pathological results showed that seven patients (37%) achieved a pCR. Ten patients (53%) experienced pathological downstaging. Pathological complete nodal response (pN0) occurred in 14 (74%) patients. The median follow-up was 28 mo (interquartile range 26-36). Disease progression or death occurred in 13 patients. Treatment-related adverse events of grade 3 or 4 accounted for 46% of complications. Limitations of this work included its single-centre, one-arm design and the absence of standardised cN+ diagnosis. Conclusions and clinical implications: The combination of tislelizumab and gemcitabine/cisplatin with consolidative RC appears to be a relatively safe neoadjuvant therapy in patients with lymph node-positive bladder cancer. Patient summary: In this study, we investigated the efficacy of neoadjuvant chemoimmunotherapy in patients with clinically lymph node-positive bladder cancer. We found that the clinical effect of completing three neoadjuvant chemoimmunotherapy sessions combined with consolidative radical cystectomy was relatively good. Our conclusion is that neoadjuvant chemoimmunotherapy combined with consolidative radical cystectomy is safe and effective for patients with clinically positive lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.